Vapourtec Sees Flow Chemistry Growth in India
News Sep 09, 2014
Pi-Process Intensification have been acting as distributors for Vapourtec's R-Series systems for the past three years and will now also be distributing their E-Series system.
Dr Reddy's Labs is one of a number of key customers. They recently took delivery of a second R-Series system, this time for their research lab in Hyderabad.
The R-Series has a wide range of applications with more than 200 systems installed and already used around the world by many major companies including BP, Pfizer, GSK, Sanofi, Novartis and Johnson & Johnson.
Pi-Process Intensification CEO Vijay Kirpalani commented: "We're delighted that our link up with Vapourtec brings the latest flow chemistry innovations to the Indian sub-continent.
"As the potential and awareness of continuous chemical processing increases, we only foresee further interest in both Vapourtec's R-Series and E-Series systems and associated products," added Vijay.
Vapourtec Sales & Application Specialist Andrew Mansfield said: "The development of a market for Vapourtec in India and South Asia suggests there is significant scope for growth in the use of flow chemistry
"Having been closely involved in the formation of a flow chemistry capability in India, it is very encouraging to see significant progress being made," added Andrew.
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE
Synthesis Strategy Could Mean Wave of New Medicinal CompoundsNews
In pharmacology, not all molecular structures are created equal. Some frameworks are overrepresented in nature, making them especially attractive to scientists on the hunt for more effective drugs. One such structure, the carbocyclic 5-8-5 fused ring system, is notoriously difficult to produce using conventional laboratory methods. Now, an innovative synthetic technique could unlock these elusive structures.READ MORE
BioAscent Secures Investment to Expand its Integrated Drug Discovery ServicesNews
£1.6m investment recognises BioAscent’s unique capabilities.READ MORE